COVID-19 neutralizing antibody in phase-1 clinical trial

A recombinant, fully human, monoclonal neutralizing antibody against COVID-19 entered into the phase I clinical trial as it was injected into the first subject on Sunday in Shanghai. The clinical trial of the antibody was approved by the National Medical Products Administration on Friday.

The phase I clinical trial will test the safety and dosage of the neutralizing antibody among healthy people. This is a clinical trial for the world-first neutralizing antibody treatment against COVID-19 among healthy people after non-human primate experiments. The neutralizing antibody is a target-pathogen that can block pathogen infecting specific immunoglobulin.

It is developed against COVID-19, and is deemed as a promising candidate both for vaccine and treatment development that has independent intellectual property rights of China.